Skip to main content

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 99 institutions reported holding it in 13F filings for Q3 2026, worth $63.0M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$187.3M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +7 vs. previous quarter
99
13F valueReported value at the end of Q3 2026
$63.0M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$2.80M
−92.8% year over year
Net income, FY2025
-$130.3M
No comparable prior period
Free cash flow, FY2025
-$79.4M
No comparable prior period
Revenue, Q3 FY2026
$0
−100.0% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $130.3M (4658.6% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.92M
Shares sold short
Change
+41.2K
+2.2% vs. previous
Days to cover
16.50
At average daily volume

Superinvestors holding RNAC, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding RNAC at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Cartesian Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 8, 2026 (view filing)Jan 62 daysBrunn CarstenPresident and CEOSSale−23.8K$6.82−$162.1K−6.8%323.5K after
Jan 8, 2026 (view filing)Jan 62 daysMiljkovic MilosChief Medical OfficerSSale−3.57K$6.82−$24.4K−5.7%58.8K after
Jan 8, 2026 (view filing)Jan 62 daysDavis BlaineChief Financial OfficerSSale−10.6K$6.82−$72.2K−8.0%121.2K after
Dec 8, 2025 (view filing)Dec 44 daysBarabe Timothy CDirectorPPurchase+30.0K$6.86+$205.8K+123.1%54.4K after
Apr 11, 2025 (view filing)Apr 9-112 daysSpringer Timothy ADirector, 10% OwnerPPurchase+22.4K$10.21+$228.3K+0.3%8.64M after5 lots
Apr 11, 2025 (view filing)Apr 9-112 daysSpringer Timothy ADirector, 10% OwnerPPurchase+126.7K$10.21+$1.29M+23.9%656.5K after5 lots
Mar 20, 2025 (view filing)Mar 18-202 daysSpringer Timothy ADirector, 10% OwnerPPurchase+89.9K$15.26+$1.37M+1.1%8.62M after3 lots
Jan 15, 2025 (view filing)Jan 13-142 daysSpringer Timothy ADirector, 10% OwnerPPurchase+21.0K$17.47+$366.4K+0.2%8.53M after3 lots
Jan 7, 2025 (view filing)Jan 3-64 daysKurtoglu MetinChief Technology OfficerSSale−4.88K$16.78−$81.8K−7.3%62.3K after2 lots
Jan 7, 2025 (view filing)Jan 3-64 daysMiljkovic MilosChief Medical OfficerSSale−1.88K$16.78−$31.5K−5.0%35.4K after2 lots

Top 10 13F holders, Q3 2026

See all 99 holders

The largest institutional positions in Cartesian Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding RNAC in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Squarepoint Ops LLC2,263,230$16.3M0.03%+8,611+0.4%Added
BlackRock, Inc.808,458$5.83M0.00%−10,781−1.3%Reduced
683 Capital Management, LLC751,000$5.41M0.52%+101,000+15.5%Added
Vanguard Capital Management LLC555,823$4.01M0.00%00.0%Unchanged
FMR LLC370,457$2.67M0.00%+2,028+0.6%Added
Two Sigma Investments, LP367,350$2.65M0.00%+71,057+24.0%Added
Geode Capital Management, LLC342,829$2.47M0.00%−13,696−3.8%Reduced
AQR Capital Management LLC287,156$2.07M0.00%−69,300−19.4%Reduced
State Street Corp261,736$1.89M0.00%+12,524+5.0%Added
Marshall Wace, LLP243,545$1.76M0.00%+10,626+4.6%Added

Holders of 5% or more of RNAC

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cartesian Therapeutics, Inc..

Largest holders of RNAC from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Springer Timothy A13D/A36.90%9.56M shares+0.10 ppfrom 36.80%May 27, 202113 filingsJan 15, 2025SEC
Kalayoglu Murat13D/A19.90%5.83M shares–Nov 22, 20234 filingsApr 2, 2026SEC
Squarepoint Ops LLC13G8.30%2.21M sharesNewMar 13, 20261 filingMar 13, 2026SEC